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ABSTRACT The formation of protein ﬁbrils, and in particular amyloid ﬁbrils, underlies many human diseases. Understanding
ﬁbril formation mechanisms is important for understanding disease pathology, but ﬁbril formation kinetics can be complicated,
making the relationship between experimental observables and speciﬁc mechanisms unclear. Here we examine one often-
proposed ﬁbril formation mechanism, nucleated polymerization with off-pathway aggregation. We use the characteristics of this
mechanism to derive three tests that can be performed on experimental data to identify it. We also ﬁnd that this mechanism has an
especially striking feature: although increasing protein concentrations generally cause simple nucleated polymerizations to reach
completion faster, they cause nucleated polymerizations with off-pathway aggregation to reach completion more slowly when the
protein concentration becomes too high.
INTRODUCTION
The formation of ﬁbrillar protein aggregates, often called
amyloid ﬁbrils, is a central feature of many human diseases
(1), including the systemic amyloidoses (2), Alzheimer’s
disease (3), and Parkinson’s disease (4) among others. The
mechanism of protein ﬁbril formation dictates the rate of
protein ﬁbril formation, the kinds of intermediates that exist
during this process (which may be more toxic than the ﬁnal
products), and how long these intermediates persist. These
factors, in turn, are likely to dictate disease onset and pro-
gression. In vitro studies of protein ﬁbrillation mechanisms
are therefore important for understanding diseases associated
with protein ﬁbril formation (5). Unfortunately, protein ﬁbril
formationmechanisms can be complicated,making it difﬁcult
to correlate experimental observations with speciﬁc mecha-
nisms. Even the simple nucleated polymerization, in which a
high-energy oligomer known as the nucleus acts as a bot-
tleneck that limits the rate of ﬁbril formation (6–9), can have
unexpected features (9). This problem is aggravated when
mechanisms include processes other than simple on-pathway
ﬁbril growth, such as formation of amorphous (i.e., non-
ﬁbrillar) aggregates. Such complications are quite common in
experimental studies of protein ﬁbril formation (10–24).
Nonﬁbrillar aggregates could play several roles in ﬁbril for-
mation mechanisms: they could be necessary for ﬁbril
formation (obligate); they could be capable of converting to
ﬁbrils but not necessary for ﬁbril formation (on-pathway); or
they could be incapable of converting directly to ﬁbrils (off-
pathway). Distinguishing among these possibilities can be
difﬁcult, but is critical for understanding ﬁbril formation
kinetics. In this report, we propose tests that can be applied to
experimental data to identify nucleated polymerizations with
competingoff-pathwayaggregation.Weuseanalytical approx-
imations and numerical solutions to the rate equations to show
that, under some conditions, nucleated polymerizations with
off-pathway aggregation have simple kinetics and we derive
equations that can be ﬁt to experimental reaction progress
data. Furthermore, we show that off-pathway aggregates re-
tard ﬁbril formation and in addition can cause the ﬁbril
formation rate to have an inverted concentration dependence;
that is, ﬁbril formation can become slower as the protein
concentration increases.
MATERIALS AND METHODS
Numerical integration of differential equations and other calculations were
performed on a personal computer with dual AMD Athlon 2200 MP
processors using Mathematica 5.2 (Wolfram Research, Champaign, IL) for
Windows XP.
RESULTS
Model
Fig. 1 is an illustration of our model for a nucleated po-
lymerization with competing off-pathway aggregation. As
indicated in Fig. 1, the monomer is denoted X1. On-pathway
species are denoted Yj (j $ 2). The nucleus consists of n
monomers and is denoted Yn; on-pathway species smaller
than the nucleus are called oligomers, and those larger than
the nucleus are called ﬁbrils. Off-pathway species are
denoted Zj (j $ 2) and are called aggregates. This model
contains the following assumptions, most of which are
common in models of protein ﬁbril formation and aggrega-
tion (7–9,25–27). 1), We assume that the sizes of both on-
pathway ﬁbrils and off-pathway aggregates change only by
monomer association or dissociation (Roberts (28) and
Andrews and Roberts (8) have recently characterized models
that include association by larger species). 2), We assume
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that addition of a monomer to the nucleus to form a ﬁbril is
irreversible (bn11 ¼ 0). This assumption enables us to treat
all of the ﬁbrils together, where the ﬁbril number concen-
tration is denoted [F(0)] (½Fð0Þ ¼ +N
j¼n11½Yj) and the amount
of monomer incorporated into ﬁbrils, or the ﬁbril amount
concentration, is denoted [F(1)] (½Fð1Þ ¼ +N
j¼n11 j½Yj). The
quantities [F(0)] and [F(1)] are the 0th and 1st moments of the
ﬁbril size distribution (29). 3), We assume that on-pathway
association rate constants are independent of size (a1 ¼
a2 ¼ a3 ¼ . . . ¼ a). We assume the same for off-pathway
association rate constants (a1 ¼ a2 ¼ a3 ¼ . . . ¼ a), but we
expect a to be larger than a: because the off-pathway
aggregates are amorphous, the orientational requirements for
monomer addition should be more relaxed than for the more
structured ﬁbrils (30–32). (Association rate constants cannot
be truly size independent, but Hill has shown that monomer-
monomer and monomer-large ﬁbril association rate con-
stants should be different by a factor of no more than two
(27).) 4), We assume that on-pathway dissociation rate
constants are the same for all oligomers (b2 ¼ b3 ¼ . . . bn ¼
b), but they decrease sharply after the nucleus (reﬂecting the
greater stability of ﬁbrils) and are constant thereafter (bn12¼
bn13 ¼ . . . ¼ c, c  b). We assume that the off-pathway
dissociation rate constants are completely size independent
(b2¼ b3¼ . . .¼ b) because, unlike the on-pathway species,
amorphous aggregates are unlikely to have structural fea-
tures that change at a critical size. 5), We assume that off-
pathway aggregates are less stable than ﬁbrils but more
stable than oligomers. We make this assumption because if
off-pathway aggregates were more stable than ﬁbrils, their
higher association rate constants would preclude ﬁbril for-
mation, whereas if they were less stable than oligomers, off-
pathway aggregation would not happen. 6), Finally, we
assume that ﬁbrils do not associate to form ﬁbril clusters
(which are sometimes observed in ﬁbril formation reactions),
or, equivalently, we assume that if such ﬁbril association
happens, it does not affect the elongation kinetics of indi-
vidual ﬁbrils in the clusters.
The relative stabilities of the species in the mechanism in
Fig. 1 can be characterized by their monomer dissociation
constants. For a ﬁbril, this dissociation constant is Kc ¼ c/a.
This quantity is also known as the ‘‘critical concentration’’
for ﬁbril formation because ﬁbril formation is negligible if
the total protein concentration ([X]tot) is ,Kc (7,24,25). The
monomer dissociation constant from an oligomer is Ks ¼
b/a. We have previously named this quantity the ‘‘supercriti-
cal concentration’’ because the monomer, not the nucleus,
becomes the highest energy species on the ﬁbril formation
pathway when [X]tot . Ks (9). Finally, the monomer
dissociation constant from an off-pathway aggregate is KA ¼
b/a. Given the ﬁfth assumption made in the preceding
paragraph, the equilibrium constants for monomer dissoci-
ation increase in the order Kc, KA, Ks (also note that b
c because Kc , KA and a . a).
The third and fourth assumptions made above guarantee
that the size of the on-pathway nucleus will be independent
of concentration (as long as [X]tot, Ks) (6,9). Such constant
nucleus size models are appropriate for ﬁbrils with structures
in which there is a sudden change in the number of contacts
made by added subunits once a critical size is reached; for
example, at the closing of the ﬁrst loop in a helical ﬁbril
(6,7,9,27,33). The nucleus is then the species one subunit
smaller than this critical size. However, for reasons given by
Ferrone (6), this model breaks down even for helical
polymers if the nucleus is too large. Thus, in this work we
treat only cases with n# 5. The third and fourth assumptions
also guarantee that off-pathway aggregation is not nucleated
(i.e., it is a downhill polymerization when [X]tot. KA), since
neither the association nor the dissociation rate constants for
this process change with aggregate size.
A ﬁnal consequence of our assumptions is that, because
off-pathway aggregation is not nucleated and because mono-
mer association and dissociation are both faster off-pathway
than on-pathway (a . a and b  c), off-pathway aggre-
gation comes to equilibrium almost before ﬁbril formation
begins. In fact, we show in the Supplementary Material that
the off-pathway aggregate size distribution approaches equi-
librium with an effective half-life (t1/2) of
t1=2 ¼ ln2
b 1
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This timescale is substantially shorter than that of ﬁbril
formation for all cases examined herein. We can therefore
treat the monomer as though it is in continuous preequili-
FIGURE 1 The nucleated polymerization mechanism of ﬁbril formation
with off-pathway aggregation. Both on-pathway (denoted Yj) and off-
pathway species (denoted Zj) are assumed to grow only by monomer
addition. The on-pathway species with n subunits (Yn) is known as the
nucleus; on-pathway species with fewer than n subunits are referred to as
oligomers, whereas those with more than n subunits are referred to as ﬁbrils.
All off-pathway species are referred to as aggregates. The letters above and
below the arrows represent rate constants for the corresponding reactions.
The rate constants in parentheses result from the assumptions in the text.
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brium with off-pathway aggregates during ﬁbril formation;
that is aggregates instantaneously compensate for any changes
in monomer concentration such that the monomer-aggregate
preequilibrium is maintained (we use the term ‘‘preequili-
brium’’ here rather than ‘‘equilibrium’’ because true equi-
librium is not reached until ﬁbril formation is complete). In
this sense, the aggregates could be said to buffer the mono-
mer concentration (see below). This result makes it convenient
to combine to the monomer and the off-pathway aggregates
into the quantity [A], the amount concentration of monomer
plus aggregates: ½A ¼ ½X11 +Nj¼2 j½Zj: The concentrations
of the Zj at equilibrium are ½Zj ¼ ½X1j=Kj1A ; so the ex-
pression for [A] can be simpliﬁed:
½A ¼ +
N
j¼1
j½X1j=Kj1A ¼
½X1K2A
ðKA  ½X1Þ2
: (2)
Solving Eq. 2 for [X1] gives the concentration of monomer
in preequilibrium with off-pathway aggregates, which we
will denote [X1]e:
½X1e ¼ KA 11
KA 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4KA½A1K2A
q
2½A
0
@
1
A: (3)
Fig. 2 is a plot of [X1]e/KA as a function of [A]/KA,
showing that [X1]e/KA asymptotically approaches 1 as [A]/KA
becomes large (i.e., [X1]e approaches KA when [A]  KA).
The rate equations for the mechanism shown in Fig. 1 are
presented in the Supplementary Material. Given the assump-
tions made above, however, these rate equations can be sim-
pliﬁed. Because monomer and off-pathway aggregates are in
preequilibrium, the rate equations for [X1] and [Zj] (j $ 2)
can be replaced by the single rate equation for [A]. Moreover,
because the monomer concentration is always below the
supercritical concentration ([X1]e # KA , Ks), the simpli-
ﬁcations made for classical nucleated polymerizations (6–8)
can be made here: the rate equations for oligomers can be
ignored because their concentrations are negligible, and, like
the off-pathway aggregates, the nucleus is in preequilibrium
with monomer ð½Yn ¼ ½X1ne=Kn1s Þ: Applying these simpli-
ﬁcations to the rate equations in the Supplementary Material
yields the following (see the Supplementary Material for
more details):
d½A
dt
¼ ðn1 1Þa½X1e½Yn  a½X1e½Fð0Þ1 c½Fð0Þ
¼ ðn1 1Þa½X1
n11
e
K
n1
s
 a½X1e½Fð0Þ1 c½Fð0Þ (4)
d½Fð0Þ
dt
¼ a½X1e½Yn ¼
a½X1n11e
K
n1
s
(5)
d½Fð1Þ
dt
¼ ðn1 1Þa½X1e½Yn1 a½X1e½Fð0Þ  c½Fð0Þ
¼ ðn1 1Þa½X1
n11
e
K
n1
s
1 a½X1e½Fð0Þ  c½Fð0Þ (6)
½Xtot ¼ ½A1 ½Fð1Þ (7)
½At¼0 ¼ ½Xtot; ½Fð0Þt¼0 ¼ 0; ½Fð1Þt¼0 ¼ 0; (8)
where [X1]e is given by Eq. 3. In the above set of equations,
Eq. 4 is the rate equation for the combined amount
concentration of monomer and off-pathway aggregates. It
comprises three terms: the ﬁrst accounts for protein passing
from the monomer/off-pathway aggregate state to the ﬁbril
state through the formation of new ﬁbrils, which consumes
n 1 1 monomers; the second accounts for protein passing
from the monomer/off-pathway aggregate state to the ﬁbril
state through monomer addition to already existing ﬁbrils;
the third accounts for protein passing from the ﬁbril state to
the monomer/off-pathway aggregate state through monomer
dissociation from ﬁbrils. Equation 5 is the rate equation for
the ﬁbril number concentration, [F(0)]. It consists of only
one positive term (reﬂecting the nucleation of new ﬁbrils)
because we have assumed that ﬁbril formation is irreversible
(see assumption 2 above). Equation 6 is the rate equation for
the ﬁbril amount concentration, [F(1)] (i.e., the amount of
protein incorporated into ﬁbrils). It is the negative of Eq. 4
because, as mentioned above, we have ignored oligomers,
leaving monomers/off pathway aggregates and ﬁbrils as the
only remaining states. Any protein that leaves one of these
states has to enter the other. This reasoning also explains Eq.
7, the mass balance equation, which states that the total pro-
tein concentration is the sum of the monomer/off-pathway
aggregate amount concentration and the ﬁbril amount con-
centration. Finally, in Eq. 8 are the initial conditions.
Equations 4–8 do not have a steady-state solution (because
d[F(0)]/dt is always positive), but steady state is most closely
approached when [X1]e ¼ c/a ¼ Kc (9). Substituting this
into Eq. 2 gives the near steady-state amount concentration
of monomer plus off-pathway aggregates, ½Ass ¼ ðKcK2AÞ=
ðKA  KcÞ2; which can be substituted into Eq. 7 to give the
FIGURE 2 The equilibrium concentration of monomer, [X1]e, in the
presence of a given amount of off-pathway aggregate, [A]. Both monomer
and off-pathway aggregate are measured relative to KA, the equilibrium
constant for monomer dissociation from an off-pathway aggregate. (Inset)
Same as above, but shown on a log scale to illustrate the asymptotic ap-
proach of [X1]e/KA to 1 as [A] increases.
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near steady-state amount concentration of ﬁbrils, ½Fð1Þss ¼
ð½Xtot  KcK2AÞ=ðKA  KcÞ2: If KA  Kc, this simpliﬁes to
[F(1)]ss¼ [X]tot Kc, which implies that the concentration of
off-pathway aggregates is negligible at steady state. Equa-
tions 4–8 are valid until the near steady-state point is
reached, but because [F(0)] continues to increase beyond this
point (whereas the actual ﬁbril number concentration should
decrease), the approximation breaks down at long times (7).
The effect of off-pathway aggregation on ﬁbril
formation kinetics: a test case and
analytical approximations
The solid curves in Fig. 3 are plots of the numerical solutions
to the rate equations for our model for a test case in which
[X]tot is varied from 1mM to 10 mM and the other parameters
are ﬁxed: n ¼ 4, Kc ¼ 100 nM, Ks ¼ 100 mM, a ¼ 106
M1s1 (b ¼ 102 s1, c ¼ 101 s1), KA ¼ 1 mM, a ¼ 107
M1s1 (b ¼ 10 s1). The progress of the reaction is shown
in terms of the fraction of protein that has been converted to
ﬁbrils ([F(1)]/[F(1)]ss), which can be determined experimen-
tally by dye binding assays discussed in more detail below.
The more complete set of rate equations in the Supplemen-
tary Material was used to obtain the numerical solutions
plotted in Fig. 3 instead of Eqs. 4–8. This was done to ensure
that our assumption that the monomer and off-pathway
aggregates are immediately and continuously in preequili-
brium does not unduly bias our examination of this
mechanism. Fig. 3 shows that the time courses of ﬁbril
formation are roughly sigmoidal at low [X]tot ([X]tot # 10
mM), with [F(1)]/[F(1)]ss increasing slowly at ﬁrst, then more
rapidly as the reaction progresses, and slowly again as ﬁbril
formation approaches completion. The appearance of the time
courses changes as [X]tot increases: at high [X]tot ([X]tot $
100 mM) the ﬁbril formation rate increases continually until
the reaction is almost complete, at which point it abruptly
drops to;0. In addition, Fig. 3 shows that the concentration
dependence of the ﬁbril formation rate is unusual. Fig. 3 F is
a log-log plot of the t50 for ﬁbril formation (the time required
for ﬁbril formation to reach 50% completion) versus [X]tot
showing that t50 initially decreases as [X]tot increases (as
expected for a ﬁbril formation reaction (7,9,25,26)), but t50
reaches a minimum at around 10 mM and then begins to
increase as [X]tot increases; that is, the approach to comple-
tion becomes slower as the protein concentration increases.
This ‘‘inverted’’ dependence of t50 on [X]tot has been
observed experimentally in the aggregation of immunoglob-
ulin light chain (22,23) and the prion protein (11).
These observations can be understood by noting that, as
several groups have observed previously (18,19,34,35), off-
pathway aggregates serve as a reservoir of protein from
which the monomer draws as it is consumed to form ﬁbrils.
The off-pathway aggregates buffer the monomer concentra-
tion, which therefore changes slowly as ﬁbrils form. Because
of this behavior, it is instructive to solve Eqs. 4–8 as though
[X1]e were constant and equal to its initial value, given by
substituting [A] ¼ [X]tot into Eq. 3:
½X1e;t¼0 ¼ KA 11
KA 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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q
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@
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Equations 4–8 are then easily solved:
½A ¼ ½Xtot 
½X1n11e;t¼0
K
n1
s
ðn1 1Þat1 ð½X1e;t¼0  KcÞ
2
a2t
2
 
(10)
½Fð0Þ ¼ ½X1
n11
e;t¼0
K
n1
s
at (11)
½Fð1Þ ¼ ½X1
n11
e;t¼0
K
n1
s
ðn1 1Þat1 ð½X1e;t¼0  KcÞ
2
a2t
2
 
: (12)
Equations 10–12 show that, as long as [X1]e ; [X1]e,t¼0,
[F(0)] increases linearly with time, [F(1)] increases as t2, and
[A] decreases as t2. Inspecting Eqs. 10–12 makes it clear that
treating [X1]e as a constant is an approximation that cannot
be valid over the entire ﬁbril formation time course, since
the expressions for [F(0)] and [F(1)] increase without bound
as t increases. Ferrone has obtained similar results using a
constant monomer concentration approximation for simple
nucleated polymerizations, and has shown that this approx-
imation is only valid for the ﬁrst 10–20% of the time course,
after which the monomer concentration begins to depart
appreciably from its initial value (25). Fortunately, when the
monomer concentration is buffered by an off-pathway
aggregation, [X1]e remains close to its initial value for larger
and larger portions of the ﬁbril formation time course as
[X]tot increases. This observation is illustrated by the long-
dashed curves in Fig. 3, which are plots of [F(1)]/[F(1)]ss
made by using Eq. 12. At low [X]tot ([X]tot¼ 1 mM, Fig. 3 A),
the approximation is good only until [F(1)]/[F(1)]ss ; 0.1.
The inset in Fig. 3 A shows that [X1]e deviates substantially
from [X1]e,t¼0 beyond this point. As [X]tot increases to
moderate values ([X]tot¼ 10–100 mM, Fig. 3, B and C), [X1]e
remains closer to [X1]e,t¼0 over more of the ﬁbril formation
time course, so Eq. 12 is valid for longer. However, Fig. 3, D
and E, show that Eq. 12 is not a good approximation to the
actual time courses as [X]tot increases beyond 100 mM,
despite [X1]e being very close to [X1]e,t¼0 throughout ﬁbril
formation.
The deviation of Eq. 12 from the numerical solutions at
high concentration can be explained by noting that the devi-
ations begin when [X]tot exceeds the supercritical concen-
tration (Ks ¼ 100 mM). At such high protein concentrations,
on-pathway oligomers become stable. The ﬁbril formation
pathway behaves initially like an irreversible downhill poly-
merization instead of a nucleated polymerization (9), and
protein ﬂoods into both the ﬁbril formation and the aggre-
gation pathways. Instead of coming to a preequilibrium, mono-
mer partitions between the pathways according to the ratio
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a/a; that is, their relative association rates control the
amounts of off-pathway and on-pathway species that form,
not their relative stabilities (we have observed similar effects
in tetramerization by competing pathways (36)). The mon-
omer concentration decreases as the reaction proceeds, and
when it is low enough the now-unstable on-pathway
oligomers dissociate in favor of off-pathway aggregates.
Preequilibrium is then established between the pathways.
However, any ﬁbrils that formed during the initial rush of
protein into the ﬁbril formation pathway are stable and
persist even after the monomer reaches equilibrium with the
off-pathway aggregates. Such ﬁbrils act as seeds for ﬁbril
formation, causing the ﬁbril formation reaction to progress
faster than would be expected based on Eqs. 10–12. This
behavior can be accounted for by changing the initial
condition for [F(0)] from [F(0)]t¼0 ¼ 0 to [F(0)]t¼0 ¼ [F(0)]0
where [F(0)]0 is a constant. Solving Eqs. 4–8 with [F
(0)]t¼0 ¼
[F(0)]0 and retaining the approximation that [X1]e¼ [X1]e,t¼0¼
constant gives the following results:
½A ¼ ½Xtot  ½Fð0Þ0ð½X1e;t¼0  KcÞat
 ½X1
n11
e;t¼0
K
n1
s
ðn1 1Þat1 ð½X1e;t¼0  KcÞ
2
a2t2
 
(13)
½Fð0Þ ¼ ½Fð0Þ01
½X1n11e;t¼0
K
n1
s
at (14)
FIGURE 3 (A–E) Plots of the extent of completion versus time for our test case at (A) [X]tot ¼ 1 mM, (B) [X]tot ¼ 10 mM, (C) [X]tot ¼ 100 mM, (D) [X]tot ¼
1 mM, and (E) [X]tot ¼ 10 mM. The extent of completion is deﬁned as the amount concentration of ﬁbrils ([F(1)]) relative to the near steady-state amount
concentration of ﬁbrils ([F(1)]ss). Solid curves represent the time courses obtained from the numerical solutions to the rate equations. Long-dashed curves
represent time courses obtained from Eq. 12. Short-dashed curves (D and E only) represent time courses obtained from Eq. 15 using values of [F(0)]0 calculated
as described in the Supplementary Material. (Insets) Plots of the monomer concentration ([X1]e) relative to initial monomer concentration ([X1]e,t¼0) as a
function of the extent of completion. (F) A plot of t50 vs. [X]tot on a log-log scale. Points represent t50 values calculated from the numerical solutions of the rate
equations. The long-dashed curve represents t50 values calculated from Eq. 16. The short-dashed curve represents t50 values calculated from Eq. 18. (Inset) An
expansion of the region around [X]tot ¼ 10 mM showing that the minimum t50 value occurs at [X]tot ¼ 10.5 mM.
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½Fð1Þ ¼ ½Fð0Þ0ð½X1e;t¼0  KcÞat
1
½X1n11e;t¼0
K
n1
s
ðn1 1Þat1 ð½X1e;t¼0  KcÞ
2
a2t2
 
: (15)
Equations 13–15 contain extra terms that are directly
proportional to [F(0)]0. The extra terms are independent of t
for [F(0)] and linear in t for [A] and [F(1)]. The inﬂuence of
the extra linear term in the expression for [F(1)] is apparent in
Fig. 3, D and E, where the numerically solved ﬁbril
formation time courses are less curved than in Fig. 3, A–C.
The value of [F(0)]0 can be estimated from ﬁrst principles, as
demonstrated in the Supplementary Material. This estimate
was used in Eq. 15 to draw the short-dashed curves in Fig. 3,
D and E. These plots show that accounting for ﬁbrils formed
during the initial wave of ﬁbril formation at high total protein
concentration ([X]tot . Ks) greatly improves the approxima-
tion to the numerical solutions. The expression for [F(0)]0 is
cumbersome and is not reproduced here (see Supplementary
Material), but we note that [F(0)]0 is directly proportional to
[X]tot, and it increases as a/a decreases (that is, as the rate of
on-pathway ﬁbril formation increases relative to off-pathway
aggregation) and as n decreases (because small nuclei make
ﬁbril formation easier).
Equations 12 and 15 (the approximate solutions for [F(1)])
can be used to explain the unusual dependence of t50 on [X]tot
alluded to above and illustrated by Fig. 3 F. A simple
estimate of t50 can be obtained by solving Eq. 12 for t when
[F(1)] ¼ [X]tot/2, the approximate halfway point for ﬁbril
formation:
t50 ¼ 1
a
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Kn1s ½Xtot
½X1n11e;t¼0ð½X1e;t¼0  KcÞ
s
: (16)
We have ignored the linear term in Eq. 12 to obtain this
equation since it becomes negligible when t 2 (n1 1) a1
([X1]e,t¼0  Kc)1, which usually happens early in the ﬁbril
formation time course (after;10 s in our test case). Equation
16 is plotted in Fig. 3 F as the long-dashed curve. Since Eq.
16 was derived from Eq. 12, all of the limitations of Eq. 12
apply to Eq. 16 as well. Equation 16 is therefore less accurate
at low and high values of [X]tot than at moderate values of
[X]tot. Nevertheless, it reproduces the most striking feature of
the dependence of t50 on [X]tot: the change from a negative to
a positive slope in the plot of t50 vs. [X]tot as [X]tot increases.
This change in slope indicates that the ﬁbril formation rate
(relative to the total protein concentration) begins to slow
down as [X]tot increases beyond a critical value. Mathemat-
ically, this behavior can be explained by the dependence of
[X1]e,t¼0 on [X]tot. The value of [X1]e,t¼0 initially increases
fairly rapidly as [X]tot increases (the initial slope of a plot of
[X1]e,t¼0 vs. [X]tot is 1; see Fig. 2). Consequently, the
denominator of Eq. 16 increases faster than the numerator
(especially since the denominator depends on the n 1 2
power of [X1]e,t¼0) and t50 decreases as [X]tot increases.
However, the dependence of [X1]e,t¼0 on [X]tot soon weakens
and [X1]e,t¼0 eventually becomes almost constant, approach-
ing KA asymptotically. The denominator of Eq. 16 also
becomes nearly constant, but the numerator continues to
increase, so t50 eventually begins to increase as [X]tot
increases. It can be shown (see Supplementary Material) that
the change in the sign of the slope of the t50 vs. [X]tot plot
happens when
½Xtot ¼
KAðn21 4n1 3Þ
4
: (17)
In our test case, n¼ 4 and KA¼ 1 mM, so according to Eq.
17 the sign change in the slope should occur at 8.8 mM. The
inset to Fig. 3 F shows that the sign change in the slope in
fact occurs at around 10.5 mM according to the numerical
solutions, matching the result from Eq. 17 to within;0.1 log
units. Physically, the explanation given above for the change
in slope in plots of t50 vs. [X]tot translates to the following.
Off-pathway aggregation limits the monomer concentration
to be ,KA, no matter how high the total protein concentra-
tion is, and therefore limits the rate of ﬁbril formation as
well. However, the amount of protein that must be converted
to ﬁbrils is not limited. The time required for ﬁbril formation
to reach 50% completion thus increases as [X]tot increases
when [X]tot is very high.
After the plot of t50 vs. [X]tot changes slope, it increases
rapidly at ﬁrst, then more slowly. This behavior is not
captured by Eq. 16, inspection of which suggests that t50
should increase with ½X1=2tot (the slope of the log-log plot
should be 11/2). Better estimates of t50 at high protein con-
centrations can be obtained by solving Eq. 15 (instead of Eq.
12) for t when [F(1)] ¼ [X]tot/2. This yields
(We have again ignored the term ½X1n11e;t¼0ðn11Þat=Kn1s
to obtain this equation. Also note that Eq. 18 is identical
to Eq. 17 when [F(0)]0¼ 0.) Equation 18 is plotted in Fig. 3 F
as the short-dashed curve. This plot shows that it is a
substantially better approximation to the t50 values at high
t50 ¼ 1
a
½Fð0Þ0ð½X1e;t¼0  KcÞ
½Xtot
1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
½Fð0Þ0ð½X1e;t¼0  KcÞ
½Xtot
 !2
1
½X1n11e;t¼0ð½X1e;t¼0  KcÞ
½XtotKn1s
vuut
2
4
3
5
: (18)
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[X]tot (.100 mM) than Eq. 17. It can therefore be used to
understand the dependence of t50 on [X]tot at high [X]tot. At
ﬁrst glance, it appears that all of the terms in the denominator
of Eq. 18 are functions of [X]tot. However, as mentioned
above, [F(0)]0 is directly proportional to [X]tot, so it can be
written [F(0)]0 ¼ f0[X]tot where f0 is a proportionality
constant. Furthermore, [X1]e,t¼0 depends weakly on [X]tot
when [X]tot is large; [X1]e,t¼0 only changes from 0.90 to 0.99
mM as [X]tot changes from 100 mM to 100 mM, so [X1]e,t¼0
can be replaced by KA in this concentration range (recall that
KA¼ 1 mM). These two observations allow us to rewrite Eq.
18 in a form that illustrates more clearly the dependence of
t50 on [X]tot at high [X]tot:
Two extremes are of interest here. If f0 is small and [X]tot
is not too large (formally, if the inequality ½Xtot  Kn11A =
Kn1s ðKA  KcÞf 20
 
holds), then the ﬁrst two terms in the
denominator can be neglected, Eq. 19 reduces to Eq. 16, and
t50 is proportional to ½X1=2tot so that the slope of a log-log plot
of t50 vs. [X]tot would be 11/2. The square-root dependence
of t50 on [X]tot can be explained by the dependence of [F
(1)]
on t2, which in turn is a consequence of the constant mono-
mer concentration (and therefore the constant rate of ﬁbril
nucleation). On the other hand, if f0 and [X]tot are both large
enough (if the inequality ½Xtot  Kn11A =ðKn1s ðKA  KcÞf 20 Þ
holds), then the last term in the denominator can be neglected
and Eq. 19 reduces to
t50 ¼ 1
2af0ðKA  KcÞ: (20)
The value of t50 is independent of [X]tot in this regime, and
a log-log plot of t50 vs. [X]tot would have a slope of 0. This
independence can be explained by noting that at such high
protein concentrations, the amount of ﬁbrils formed during
the irreversible polymerization stage of the ﬁbril formation
time course is much larger than the amount of ﬁbrils nu-
cleated during preequilibrium. Consequently, only the term
[F(0)]0([X1]e,t¼0 Kc)at¼ f0[X]tot([X1]e,t¼0 Kc)at in Eq. 15
is signiﬁcant, so [F(1)] depends linearly on t with a slope that
is proportional to [X]tot. Thus, the time it takes [F
(1)] to reach
0.5[X]tot has to be independent of [X]tot. To summarize our
analysis of the dependence of t50 on [X]tot: t50 initially
decreases as [X]tot increases, as expected for ﬁbril formation
reactions, but it reaches a minimum at a concentration given
approximately by Eq. 17 and then increases. Beyond this
point, a log-log plot of t50 vs. [X]tot should have a positive
slope of at most 11/2, which should decrease gradually
toward 0 as [X]tot increases. This behavior is observed over a
wide range of parameter values, although it changes subtly
when Ks/KA becomes larger than;1000 (see Supplementary
Material).
Connection to experiment: experimentally
measurable quantities
Before discussing how the results in the preceding section
can be used to identify a nucleated polymerization with off-
pathway aggregation, we will discuss the techniques avail-
able to measure the quantities that are accessible from the
analysis above. The time-dependent value of [F(1)]/[F(1)]ss,
which corresponds to the fraction completion of a ﬁbril
formation reaction and is accessible from Eqs. 12 or 15, can
be determined experimentally using the binding of certain
dyes to amyloid ﬁbrils (e.g., thioﬂavin T (37,38)). For pro-
teins that do not precipitate during ﬁbril formation, fraction
completion also can be measured by spectroscopic tech-
niques like circular dichroism (CD), or any other technique
that responds linearly to the concentration of amyloid. Whether
dye binding, CD spectroscopy, or some other technique is
used, the fraction completion, which we will denote x, is
given by
x ¼ ðSt  SiÞðSf  SiÞ ¼
½Fð1Þ
½Fð1Þss
; (21)
where St is the signal measured by the chosen technique at
time t, Si is the signal at t¼ 0, and Sf is the signal at the end of
the ﬁbril formation reaction. The t50 of a ﬁbril formation
reaction, which is accessible from Eqs. 16 or 18, can be
determined experimentally by identifying the time at which
x, measured as described above, is equal to 0.5. Finally, an
expression for the time dependence of the intensity of
scattered light from a nucleated polymerization with an off-
pathway aggregation can be derived using the assumption of
preequilibrium between monomers and amorphous aggre-
gates and Eqs. 13 or 17 (see below). Other quantities relevant
to ﬁbril formation reactions, like the monomer concentration
(39–41) or the ﬁbril size distribution (42,43), can also be mea-
sured. However, our analysis did not yield simple expres-
sions for the time dependence of either of these quantities, so
we will focus on using x, t50 values, and light scattering for
identifying ﬁbril formation mechanisms.
Connection to experiment: the use of x vs. t data
Equation 15 shows that x ¼ [F(1)]/[F(1)]ss should have a qua-
dratic time dependence as long as [X1]e is close to its initial
t50 ¼ 1
a f0ðKA  KcÞ1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðf0ðKA  KcÞÞ21Kn11A ðKA  KcÞ½X1totKn11s
q : (19)
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value. It should therefore be possible to ﬁt at least part of a
plot of x vs. t to the equation
x ¼ C1t1C2t2: (22)
Of course, this is also true for nucleated polymerizations
(25,44), so a good ﬁt of Eq. 22 to the early portion of an
experimental ﬁbril formation time course alone cannot be
used to identify a nucleated polymerization with an off-
pathway aggregation. A stronger test for the existence of an
off-pathway aggregation is to ﬁt plots of x vs. t at a series of
increasing total protein concentrations. As [X]tot increases,
the ﬁt of Eq. 22 to x vs. t plots should improve (that is,
extend to larger and larger portions of the time course) if
there is off-pathway aggregation. Fig. 4 illustrates this point.
Fig. 4, A–C, are plots of synthetic data generated by adding a
small, Gaussian-distributed error (m ¼ 0, s ¼ 0.02) to the
numerical solutions of the rate equations for the test case
described above with [X]tot¼ 1, 10, and 100 mM. The curves
in Fig. 4, A–C, are ﬁts of Eq. 22 to the data over increasing
portions of the time course. For example, the red curve in
Fig. 4 A is the ﬁt of Eq. 22 to the data up to x ¼ 0.2, the
orange curve to its right is the ﬁt of Eq. 22 to the data up to
x ¼ 0.4, etc. Fig. 4, A–C, show that the ﬁt of Eq. 22 to the
data improves (in the sense that a good ﬁt to the data is
maintained to higher values of x) as [X]tot increases. This
observation is quantiﬁed in Fig. 4 D, which is a plot of the
root mean-square (RMS) residuals of the ﬁts in Fig. 4, A–C.
At [X]tot ¼ 1 mM (i.e., for the data in Fig. 4 A), the RMS
residuals are roughly constant for ﬁts of Eq. 22 to the data up
to x ¼ 0.4, but they increase thereafter indicating deterio-
ration in the quality of the ﬁt. For [X]tot ¼ 10 mM (Fig. 4 B),
good ﬁts are maintained to x ¼ 0.7, and for [X]tot ¼ 100 mM
(Fig. 4 C), good ﬁts are maintained essentially until the reac-
tion is complete. The improvement in the ﬁt of Eq. 22 to
x vs. t data as [X]tot increases is a better indication of off-
pathway aggregation than the ﬁt itself at a single value of [X]tot.
It is usually desirable to use the parameters from ﬁts to
experimental data to estimate quantities that are fundamental
to a mechanism. Based on Eq. 15 (the more general of the
two equations for [F(1)]), the relationships of C1 and C2 to
fundamental quantities are
C1 ¼
að½Fð0Þ
0
ð½X1e;t¼0  KcÞ1 ½X1n11e;t¼0ðn1 1ÞKn11s Þ
½Fð1Þss
;
(23)
and
C2 ¼
a
2½X1n11e;t¼0ð½X1e;t¼0  KcÞ
2K
n1
s ½Fð1Þss
: (24)
Unfortunately, Eqs. 23 and 24 show that C1 and C2 are
complicated functions of several parameters, one of which
([X1]e,t¼0) is itself a complicated function of another
parameter (KA). Unless some parameters are determined
independently, it is unlikely that even, for example, deter-
mining C1 and C2 as functions of concentration would
provide reliable estimates of n, Ks, KA, etc. A better method
to estimate parameters is discussed below.
FIGURE 4 (A–C) Plots of the extent of completion versus time to simulate ﬁts of Eq. 22 to experimental data at (A) [X]tot ¼ 1 mM, (B) [X]tot ¼ 10 mM, and
(C) [X]tot ¼ 100 mM. The gray points are from the numerical solutions to the test case with Gaussian-distributed errors (m ¼ 0, s ¼ 0.02) added to simulate
experimental data. The colored curves are ﬁts of Eq. 22 to increasing portions of the data: red, orange, green, blue, and purple curves are ﬁts up to x ¼ 0.2, 0.4,
0.6, 0.8, and 1.0, respectively. (D) A plot of the root mean-square (RMS) residuals versus the maximum value of x used in the ﬁts in A (red circles), B (green
circles), and C (blue circles) (note that the RMS residuals are only calculated for the portion of the data that was actually used in the ﬁt).
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Connection to experiment: the use of t50 vs.
[X]tot data
Log-log plots of t50 (or similar quantities) versus [X]tot are
among the most important tools for studying ﬁbril formation
reactions because they conveniently summarize the overall
concentration dependence of the rate, and t50 values are
easily measured (9,20,21,39,40). This feature makes such
plots useful for determining the nucleus size in simple
nucleated polymerizations: log-log plots of t50 vs. [X]tot are
linear when Kc , [X]tot  Ks with a slope ¼ (n 1 1)/2.
Curvature in log-log plots of t50 vs. [X]tot for a simple
nucleated polymerization indicates either that the nucleus
size is changing (if n is concentration dependent) (6,45,46)
or that [X]tot is approaching Ks (if n is ﬁxed) (9). Log-log
plots of t50 vs. [X]tot are similarly useful for studying ﬁbril
formation reactions that are not simple nucleated polymer-
izations. Log-log plots of t50 vs. [X]tot in which the slope
changes from negative to positive or in which the slope is
positive throughout are strongly indicative of off-pathway
aggregation. In the latter case, when the slope of the plot is
always positive, the indication is even stronger if the plot can
be ﬁt to the equation
t50 ¼ 1
C31
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
C231C4½X1tot
q : (25)
This equation is based on Eq. 19. (Note that this equation
should be valid only when [X]tot  KA, in which case
[X1]e,t¼0 ; KA, [F
(1)]ss ; [X]tot, and ½Fð0Þ0ð½X1e;t¼0
KcÞ  ð½X1n11e;t¼0ðn11ÞÞ=Kn1s : Comparing Eq. 19 to Eqs. 23
and 24 then reveals that C3 ¼ C1 and C4 ¼ [X]totC2.) In the
former case, when the plot of t50 vs. [X]tot includes the region
where the slope changes, inserting Eq. 9 into Eq. 16 yields an
equation that can in principle be used to obtain estimates of n
and KA (a and Ks cannot be determined independently).
However, the equation is complicated and the parameter
estimates obtained by using it are only moderately accurate.
Better (though not perfect) estimates of n can be obtained by
two methods if the initial monomer concentration in
equilibrium with off-pathway aggregates ([X1]e,t¼0) can be
measured independently by using, for example, gel ﬁltration
early in the ﬁbril formation time course. In the ﬁrst method,
the approximation ([X1]e,t¼0  Kc) ; [X1]e,t¼0 is made and
Eq. 16 is rewritten as follows
log10t50 
log10½Xtot
2
¼ C5  n1 2
2
log10½X1e;t¼0; (26)
where C5 is a constant equal to 0.5 (n  1) log10 Ks/a. The
value of n can then be estimated from the slope of a plot of
log10 t50 0.5 log10 [X]tot vs. log10 [X1]e,t¼0. Alternately, the
value of KA can be estimated by measuring [X1]e,t¼0 at a
series of total protein concentrations and ﬁtting Eq. 9 to a
plot of [X1]e,t¼0 vs. [X]tot. Given such an estimate of KA and
the value of [X]tot at which t50 is a minimum, n can be
estimated using Eq. 17.
Connection to experiment: the use of light
scattering data
The total intensity of scattered light from protein solutions
undergoing a nucleated polymerization with off-pathway
aggregation is the sum of the intensities of the light scattered
by off-pathway aggregates and ﬁbrils. Light scattering by
particles in solution depends on a number of factors, the most
important for our purposes being the particle shape and size
relative to the wavelength of incident light (l), or rather,
particle size relative to the quantity l/[2p sin (u/2)], where u
is the angle of detection (for the sake of argument in the
paragraphs that follow, we take l ¼ 500 nm and u ¼ 90 so
that l/[2p sin (u/2)] ; 110 nm).
Off-pathway aggregates are likely to be small relative to l/
[2p sin (u/2)] for two reasons. First, off-pathway aggregates
are expected to be roughly spherical, so their linear dimen-
sions (i.e., their diameters, D) should scale with the cube root
of their masses, and therefore with the cube root of the
number of subunits in the aggregates; that is, for Zj, D } j
1/3.
Second, the size-average size of the off-pathway aggregates
ðÆ jæw;aggÞ is
Æ jæw;agg ¼
+
N
j¼1
j
2½Zj
+
N
j¼1
j½Zj
¼
+
N
j¼1
j
2½X1je=Kj1A
½A ¼
½A
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4½AK1A 1 1
q
½A
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4½AK1A 1 1
q
: (27)
(We use the phrase ‘‘size-average size’’ here to mean the
weight-average molecular weight divided by the molar mass
of a monomer.) The value of [A], and therefore Æ jæw;agg; is
largest at the beginning of the ﬁbril formation reaction, when
[A] ¼ [X]tot. The maximum value of Æ jæw;agg is therefore
proportional to the square root of [X]tot/KA. Combining these
two points reveals that the average diameter of off-pathway
aggregates should only increase as the sixth root of [X]tot/KA.
Globular proteins typically have densities around 1.4 g/cm3
(47); assuming that off-pathway aggregates are packed at
least 10% as efﬁciently as globular proteins (density ;0.14
g/cm3) and that the molar mass of a monomer is ;10 kDa, a
rough calculation indicates that [X]tot/KA would have to be
on the order of 1000 for the average off-pathway aggregate
to have D ; 25 nm, or ;20% of l/[2p sin (u/2)].
Because off-pathway aggregates are small relative to l/
[2p sin (u/2)], the intensity of light scattered by them (is,agg)
depends on the second moment of their size distribution (48):
is;agg ¼ Q+
N
j¼1
j
2½Zj ¼ Q ½A
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4½AK1A 1 1
q 
; (28)
where Q is a constant that depends on the index of refraction
of the solution, the refractive index increment of the protein,
the wavelength and intensity of incident light, the distance
from the sample to the detector, and the angle of detection. If
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4½AK1A  1; as it is in the test case for much of the ﬁbril
formation time course if [X]tot is large enough ([X]tot . 10
mM), this simpliﬁes to
is;agg ¼ 2QK1=2A ½A3=2: (29)
In contrast to off-pathway aggregates, ﬁbrils are expected
to have linear dimensions (i.e., lengths, L) that become larger
than l/[2p sin (u/2)] early in the ﬁbril formation time course.
It can be shown (see Supplementary Material) that the
intensity of light scattered by ﬁbrils (is,ﬁb) in this size range
(assuming they can be treated as thin, stiff rods) should be
directly proportional to [F(1)], the ﬁrst moment of ﬁbril size
distribution (49):
is;fib ¼
Q+
N
j¼1
j½Yj
4ll
1
sinðu=2Þ ¼
Q½Fð1Þ
4ll
1
sinðu=2Þ; (30)
where l is the length increment per subunit for ﬁbrils. To
support our statement that ﬁbril lengths can rapidly become
larger than l/[2psin(u/2)], we show in the Supplementary
Material that the size average size of ﬁbrils increases with
time roughly as follows:
Æ jæw;fib ¼
+
N
j¼1
j
2½Yj
+
N
j¼1
j½Yj
ﬃ 2að½X1e;t¼0  KcÞt
3
: (31)
For the test case, with a¼ 106 M1 s1 and Kc¼ 100 nM,
the right-hand side of Eq. 31 is ;0.2t at [X]tot ¼ 1 mM
([X1]e,t¼0 ¼ 380 nM). We assume that a ﬁbrillogenic protein
with a molar mass of 10 kDa will form ﬁbrils that extend by
;1 nm for every two subunits added, giving a mass-per-
length that is roughly typical of amyloid ﬁbrils (20 kDa/nm)
(50–53). According to Eq. 31, the average ﬁbril length for
such a protein will be 200 nm (Æ jæw;fib ¼ 400) after ;2000 s
at [X]tot ¼ 1 mM. This rough calculation indicates that the
ﬁbrils formed in the test case will be substantially larger than
l/[2p sin (u/2)] well before t50 is reached (l/[2p sin (u/2)] is
exceeded even faster at higher protein concentrations).
Given the assumptions and approximations made above,
the total intensity of light scattered by a mixture of off-
pathway aggregates and ﬁbrils (is,tot) should be
is;tot ¼ is;agg1 is;fib ¼ 2QK1=2A ½A3=21
Q½Fð1Þ
4ll
1
sinðu=2Þ; (32)
where l is ;0.5 nm in our example. Noting that [F(1)] ¼
x[F(1)]ss and [A] ¼ [X]tot  [F(1)] ¼ [X]tot – x[F(1)]ss and
using Eq. 22 for x reveals that the time dependence of is,tot
has the form:
is;tot ¼ ðQ1  Q2t  Q3t2Þ3=21Q4t1Q5t2; (33)
where Q1 ¼ ð2QK1=2A Þ2=3½Xtot; Q2 ¼ ð2QK1=2A Þ2=3 ½Fð1Þss
C1;Q3¼ð2QK1=2A Þ2=3½Fð1ÞssC2;Q4¼ ðQ½Fð1ÞssC1Þ=ð4ll1
sinðu=2ÞÞ; andQ5¼ðQ½Fð1ÞssC2Þ=ð4ll1sinðu=2ÞÞ; and C1
and C2 are the same constants used in Eq. 22. If a protein
forms ﬁbrils by a nucleated polymerization with an off-
pathway aggregation, it should be possible to ﬁt Eq. 33 to a
plot of scattered light intensity versus time, but all of the
limitations of Eq. 22 apply to Eq. 33. Thus, Eq. 33 should ﬁt
to only the initial part of the scattered light intensity time
course at low [X]tot, but the ﬁt should improve (i.e., ﬁt to
larger and larger portions of the time course) as [X]tot
increases. Also, it is worth noting that only four of the ﬁve
parameters in Eq. 33 are independent, because Q2/Q3 ¼ Q4/
Q5¼ C1/C2. It could be helpful when ﬁtting Eq. 33 to data to
replace Q4 with Q2Q5/Q3, thereby reducing by one the
dimensionality of the search for best-ﬁt parameters.
DISCUSSION
Identifying a nucleated polymerization with an
off-pathway aggregation
Whether nonﬁbrillar aggregates appear during a ﬁbril forma-
tion reaction can be determined directly by using atomic
force or electron microscopy. These techniques, however,
are not as useful for determining the role of these aggregates
in a ﬁbril formation mechanism as they are for establishing
their existence. In the Results section, we presented three
tests that can be applied to experimental data to identify off-
pathway aggregates. These are: 1), Fitting Eq. 22 to x vs. t
data obtained at a series of total protein concentrations. An
improving ﬁt as [X]tot increases is an indication that the
aggregates are off-pathway. (Note that a good ﬁt throughout
the time course that remained good as [X]tot increased would
also be an indication of off-pathway aggregation). 2), Mak-
ing a log-log plot of t50 vs. [X]tot. A change in slope from
negative to positive, or a positive slope throughout that can
be ﬁt by Eq. 25 indicates that the aggregates are off-pathway.
The plot can also be used to estimate n and KA, especially if
[X1]e,t¼0 can be measured independently (see above). 3),
Fitting Eq. 33 to light scattering intensity versus t data. In
this test, a good ﬁt of the equation to the data is itself an
indication that the aggregates are off-pathway, which be-
comes stronger if the ﬁt improves as [X]tot increases.
It is difﬁcult to categorize positive results in the tests listed
above as necessary and/or sufﬁcient for identifying off-
pathway aggregation because the effects of other types of
aggregates (on-pathway or obligate) on the relevant experi-
mental observables have not been determined to our knowl-
edge. A positive result in the ﬁrst test is certainly necessary,
but may not be sufﬁcient. A positive result in the second test
may be sufﬁcient, but because high values of [X]tot may be
required to observe the sign change in the slope of a log-log
plot of t50 vs. [X]tot, it is not necessary. Similarly, a positive
result in the third test may be sufﬁcient but cannot be
considered necessary. Several approximations about how
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ﬁbrils and off-pathway aggregates scatter light were used to
derive Eq. 33; a conspiracy of unfortunate conditions could
result in these approximations becoming invalid even if the
mechanism were in fact a nucleated polymerization with off-
pathway aggregation. (For example, ﬁbrils are perhaps better
approximated as semiﬂexible chains (54,55) than thin, stiff
rods. Also, at high concentrations, interactions between ﬁbrils
could ruin the proportionality between light scattering and
[F(1)].) These tests are likely to be useful in different si-
tuations. For example, time-dependent light scattering inten-
sities are best measured with a light scattering photometer
(although they can be measured with an ordinary ﬂuorometer
(56)). Acquiring this type of data therefore has more intensive
instrumentation requirements than measuring x vs. t by dye
binding. Hence, the ﬁrst two tests are more accessible than the
third. On the other hand, if off-pathway aggregates interfere
with the dye binding assays used to measure x vs. t (for
example, we have observed binding to amorphous aggregates
to induce thioﬂavin T ﬂuorescence (12,39,40,57)) then the
third test may be the only option. Finally, if concentrations
high enough to cause the log-log plot of t50 vs. [X]tot to change
slope cannot be reached practically, the ﬁrst and third tests
would be more useful than the second. We currently believe
that a robust identiﬁcation of off-pathway aggregation should
ideally involve direct observation of nonﬁbrillar aggregates
that eventually disappear in favor of ﬁbrils and positive results
with two of the above three tests.
Off-pathway aggregates versus
off-pathway micelles
Nonﬁbrillar aggregates formed by proteins are often cate-
gorized as micelles (18,19,34,58–60). Micelles differ from
the downhill-type aggregates in our model in that they have a
preferred size (61,62). This preferred size is usually large
enough for micelle formation to behave like a phase tran-
sition: micelles do not form when the protein concentration is
below a certain concentration, called the critical micelle con-
centration (61,62). Above the critical micelle concentration,
the monomer concentration is roughly constant and excess
protein forms micelles. Off-pathway micelles should there-
fore buffer the monomer concentration just as off-pathway
aggregates do, and ﬁbril formation by proteins that form off-
pathway micelles should have characteristics similar to those
of ﬁbril formation by proteins that form off-pathway ag-
gregates. These characteristics should include a quadratic
dependence of x on t when the total protein concentration is
substantially higher than the critical micelle concentration,
and log-log plots of t50 vs. [X]tot in which the slope changes
from negative to positive at some concentration. There is,
however, one caveat: the behavior described above would
not be observed if the off-pathway micelles formed by a
protein were small (e.g., dimers, trimers, etc.), because then
‘‘micelle’’ formation would have the properties of a ﬁnite
oligomerization rather than a phase transition (monomer-
dimer, monomer-trimer, etc. equilibria do not have critical
concentrations). Compared to mechanisms with monomer-
off-pathway aggregate or monomer-micelle equilibria, the
monomer concentration would change rapidly as protein was
consumed by ﬁbril formation in a mechanismwith a monomer-
off-pathway small oligomer equilibrium, especially at high
total protein concentration. Monomer-small oligomer equi-
libria cannot buffer the monomer concentration as effec-
tively as monomer-aggregate or monomer-micelle equilibria
can.
Implications of off-pathway aggregation
Off-pathway aggregation substantially slows ﬁbril formation
reactions. In the test case examined above, using the
parameters listed in the Results section and [X]tot ¼ 10
mM, the t50 for ﬁbril formation was 93,000 s, or ;25 h. A
simple nucleated polymerization with the same parameters
would be three orders of magnitude faster, with a t50 of;80 s
(data not shown). Furthermore, the t50 of 93,000 s quoted
above was obtained with a, the monomer-ﬁbril association
rate constant, set to 106 M1 s1, which is a typical protein-
protein association rate constant (31,63). However, associa-
tion rate constants two and three orders of magnitude smaller
have also been reported (64). Changing a to 104 M1 s1 and
adjusting the other kinetic parameters so that Kc, Ks, and KA
remain constant (i.e., setting c ¼ 103 s1, b ¼ 1 s1, a ¼
105 M1 s1, and b ¼ 101 s1) would give a t50 of ;110
days. On-pathway and obligate aggregates are not expected
to slow ﬁbril formation in this way, or to persist for nearly as
long as off-pathway aggregates.
We expect that nucleated polymerization with off-path-
way aggregation will be found to be a rare ﬁbril formation
mechanism, as off-pathway aggregates ought to be able to
rearrange into on-pathway oligomers or ﬁbrils. However, for
proteins that are found to aggregate by a mechanism that
approaches nucleated polymerization with off-pathway ag-
gregation (because rearrangement is either slow or nonex-
istent), the potentially long lifetimes of the aggregates could
have important implications for protein aggregation diseases.
Nonﬁbrillar protein aggregates have been found in many
contexts to be more toxic than ﬁbrils (65–70). Proteins that
form aggregates that convert slowly and indirectly into ﬁbrils
would therefore be expected to be more harmful than those
that form aggregates that convert rapidly and directly, or
those that form ﬁbrils without nonﬁbrillar intermediates. Off-
pathway aggregates are more dangerous than on-pathway or
obligate aggregates in this sense. Worse, off-pathway
aggregates can become even longer lived as the protein
concentration increases. Off-pathway aggregates can thus be
doubly detrimental: their lifetimes can increase as they
become more abundant. These features of off-pathway
aggregates give nucleated polymerization with an off-
pathway aggregation the potential to be a particularly malign
ﬁbril formation mechanism.
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